EMA Withdrawn: Filgrastim ratiopharm (filgrastim) — Ratiopharm GmbH

View source ↗

Summary

Withdrawn European medicines agency status for filgrastim ratiopharm by Ratiopharm GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Hematopoietic Stem Cell Transplantation

Drugs mentioned

• filgrastim ratiopharm (filgrastim)

Snippet

Status: Withdrawn. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: Ratiopharm GmbH. Decision date: 20/04/2011